Van Cleef Asset Management Inc Grows Holdings in Eli Lilly and Company (NYSE:LLY)

Van Cleef Asset Management Inc grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 18.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,676 shares of the company’s stock after acquiring an additional 575 shares during the period. Van Cleef Asset Management Inc’s holdings in Eli Lilly and Company were worth $2,143,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of LLY. JGP Wealth Management LLC increased its holdings in Eli Lilly and Company by 0.9% in the fourth quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock valued at $1,074,000 after buying an additional 16 shares during the last quarter. Walkner Condon Financial Advisors LLC raised its position in shares of Eli Lilly and Company by 2.8% during the 3rd quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company’s stock valued at $334,000 after acquiring an additional 17 shares in the last quarter. Patton Albertson Miller Group LLC lifted its stake in Eli Lilly and Company by 2.8% during the third quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock worth $335,000 after purchasing an additional 17 shares during the last quarter. Valley Wealth Managers Inc. increased its stake in Eli Lilly and Company by 1.3% during the third quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock valued at $688,000 after purchasing an additional 17 shares during the last quarter. Finally, Sandy Cove Advisors LLC lifted its position in shares of Eli Lilly and Company by 0.8% in the 4th quarter. Sandy Cove Advisors LLC now owns 2,241 shares of the company’s stock worth $1,307,000 after buying an additional 17 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the transaction, the insider now directly owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.13% of the stock is currently owned by insiders.

Analysts Set New Price Targets

LLY has been the topic of a number of recent analyst reports. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. BMO Capital Markets upped their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Bank of America raised their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. The Goldman Sachs Group boosted their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Finally, Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Stock Down 1.0 %

NYSE:LLY traded down $7.33 during trading hours on Thursday, hitting $724.87. 2,597,583 shares of the stock traded hands, compared to its average volume of 3,034,002. The firm has a 50 day moving average price of $763.40 and a 200 day moving average price of $664.52. The firm has a market cap of $688.74 billion, a price-to-earnings ratio of 124.61, a PEG ratio of 1.63 and a beta of 0.34. Eli Lilly and Company has a fifty-two week low of $370.68 and a fifty-two week high of $800.78. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the prior year, the business earned $2.09 EPS. The business’s revenue for the quarter was up 28.1% on a year-over-year basis. Equities research analysts anticipate that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.